Under the assumption that in schizophrenia a pathological enhancement of the facilitatory allosteric receptor–receptor interactions develops in the D2R-5-HT2AR heterocomplexes involving nucleus accumbens [25], these receptor complexes become of high interest as targets in the treatment of schizophrenia. Here, DRD2 is linked to schizophrenia.